Dr. Maria G. Castro, PhD, co-organized and co-chaired the NIH-NINDS (National Institute of Neurological Disorders and Stroke) symposium on “What about G34R/V Mutated Gliomas?: Challenges and Opportunities”. Together with Dr. Pedro Lowenstein, M.D., Ph.D., they presented the results of the first-in-human clinical trial of a combined immune-mediated gene therapy (Ad-TK + Ad-Flt3L) for the treatment of adult primary glioblastoma. Dr. Lowenstein talked about plans to implement it in pediatric brain tumor patients very soon. Dr. Castro gave insights on the basic and translational work that led to the FDA approval for the trial.
